2 not yet recruiting, 2 recruiting, 2 unknown. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Not yet recruiting 2, Recruiting 2, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Wang Xin: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Becotatug Vedotin Plus Pucotenlimab and Capecitabine Followed by Concurrent Chemoradiotherapy-Immunotherapy for Locally Advanced Squamous Cell Carcinoma of the Anal Canal Induction therapy, Concurrent chemoradiotherapy-immunotherapy, Maintenance therapy - Squamous Cell Carcinoma of the Anal Canal | Phase 2 | Not yet recruiting | Wang Xin | 34 | 2026-09-20 | 2026-09-08 |
| Short-course RT Followed by NALIRIFOX Plus Pucotenlimab as Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer With MSS/pMMR iTNT-HX02 - Advanced Rectal Cancer | Phase 2 | Not yet recruiting | Wang Xin | 29 | 2026-05-31 | 2026-06-16 |
| PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy Tislelizumab Combined With TKI, Fecal Microbiota Transplantation, PULSAR - Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | Wang Xin | 64 | 2026-04-15 | 2026-09-02 |
| PULSAR Combined With Immunotherapy and Chemotherapy Iparomlimab and Tuvonralimab Injection (QL1706), PULSAR - Cholangiocarcinoma | Phase 1 / Phase 2 | Recruiting | Wang Xin | 60 | 2025-11-04 | 2025-12-18 |
| Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT CD25 treatment, low-dose ATG - GVHD | Phase 2 | Unknown | Wang Xin | 40 | 2024-03-26 | 2024-03-28 |
| Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma Orelabrutinib - CLL/SLL | Unknown | Wang Xin | 20 | 2023-07-01 | 2023-06-27 |
Carcinoma, Hepatocellular (1) · Cholangiocarcinoma (1)
DEAE-Dextran (2) · Drug Therapy (1) · Fecal Microbiota Transplantation (1) · Maintenance (1) · Neoadjuvant Therapy (1) · orelabrutinib (1)
China (5)
Xin Wang (1)
PMID 30284906, PMID 31192355, PMID 33119477, PMID 33301740, PMID 33862000, PMID 35263150, PMID 37902752